# Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma

> **NCT03406247** · PHASE2 · RECRUITING · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 140 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03406247
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-12
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03406247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03406247, "Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03406247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*